Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

AI Briefing

• – Net proceeds to fund commercialization of Symvess in vascular trauma indication and Phase 3 results in hemodialysis.
• – Funding will be used to support ongoing clinical trials and regulatory submissions.
• – Expected to support long-term growth and expansion of the company.